US Pharmaceutical Industry Report, 2008-2009
  • Apr/2009
  • Hard Copy
  • USD $899
  • Pages:117
  • Single User License
    (PDF Unprintable)       
  • USD $999
  • Code: ZQ003
  • Enterprise-wide License
    (PDF Printable & Editable)       
  • USD $1,499
  • Hard Copy + Single User License
  • USD $1,099
The United States has the largest pharmaceutical industry in the world. In 2007, its pharmaceutical revenue totaled at US$ 315 billion.

Global Pharmaceutical Output Value and Profits by Region, 2007

In the past decades, the structure of American pharmaceutical industry has changed dramatically caused by the aging of population, the emerging of bio-pharmaceutical technology and fierce global competition. The key players in the United States including Pfizer, GlaxoSmithKline, Johnson & Johnson, Merck, etc.


American pharmaceutical companies paid great attention to R & D due to the free market competition and patent protection of new medicines in the US. Since the year of 2000, the pharmaceutical R & D expenditure has been maintaining an increase, even in 2008, impacted by the global financial crisis, the pharmaceutical R & D expenditure totaled at US $65.2 billion, up 3.16% of last year.

There are 2,900 drugs currently in research in US, among which 750 are anticancer drugs, 312 drugs are for heart diseases, 150 are diabetes drugs and 109 are AIDS drugs, the rest 91 drugs are for the Alzheimer and senile dementia diseases.

In 2009, the sales growth of drugs in the United States is expected to around 1% ~ 2%. The growth of biotechnology, special drugs and generic drugs will be higher than the average.

The report focus on the 30 pharmaceutical companies in the United States, including their profiles, revenue and profit, as well as their products, market distribution and development strategies.

1. Current Status and Prospects of US Pharmaceutical Industry 
2. Pfizer Inc 
3. Glaxo Smith Kline
4. Merck &Co.
5. Johnson & Johnson
6. Eli Lilly and Co
7. EpiCept Corporation
8. Schering Plough Corp
9. Forest Laboratories Inc
10. Mylan Inc
11. Herbalife Ltd
12. King Pharmaceuticals Inc
13. NBTY Inc
14. Perrigo Co
15. Life Technologies Corp
16. Sepracor Inc
17. Endo Pharmaceuticals Holdings Inc
18. Warner Chilcott Ltd
19. Par Pharmaceutical Companies Inc
20. Valeant Pharmaceuticals International
21. Chattem Inc
22. Prestige Brands Holdings Inc
23. Medicines Co
24. Techne Corp
25. Cambrex Corp
26. Allion Healthcare Inc
27. Salix Pharmaceuticals Ltd
28. PDL BioPharma Inc
29. Albany Molecular Research Inc
30.Enzon Pharmaceuticals Inc
31. AmerisourceBergen Corp
Profit Pool of world’s pharmaceutical sector,2007
Top companies by U.S Sales,2007
Biopharmaceutical Companies’ investment in R&D, 1980-2008
R&D as a Percentage of Sales, PhRMA Member Companies, 2000–2008
Number of Compounds in Development by Region*
Domestic R&D Source, PhRMA Member Companies,2007
Biologics and Biotechnology R&D, PhRMA Member Companies,2007
2007 Channel Distribution by U.S Sales
Pfizer Revenue by Business Segments,2006-2008
Change in Pfizer’s Revenues by Segment and Geographic Area,2006-2008
Revenue and net profit of Pfizer Inc, 2004-2008
Analysis of the Consolidated Statement of Income of Pfizer, 2006-2008
2008 Turnover summary by segment
GSK 2008 Turnover summary by geography
GSK Pharmaceutical turnover analysis,2007-2008
GSK Pharmaceutical key growth products,2007-2008
GSK Market share growth in Emerging Markets,2008
GSK Product pipeline,2007-2008
Revenue and net profit of GSK,2004-2008
Financial performance of GSK,2007-2008
Product sales of Merck, 2006-2008
Merck patent protection products
Research pipeline of Merck as of Feb.15,2009
Revenue and net profit of Merck, 2004- 2008
Sales of Johnson & Johnson, 1998-2008
Sales of Johnson & Johnson by Geographic Region, 1998-2008
Consumer segment sales of Johnson & Johnson, 2008
Consumer segment sales of Johnson & Johnson, 2006-2008
Pharmaceutical segment sales of Johnson & Johnson, 2008
Major Pharmaceutical Product revenues of Johnson & Johnson, 2006-2008
Medical Devices& Diagnostics segment of Johnson & Johnson, 2008
Major Medical Devices& Diagnostics Franchise sales of Johnson & Johnson, 2006-2008
R&D expense of Johnson & Johnson, 2006-2008
Johnson & Johnson Operating profit by segment, 2007-2008
Eli Lilly Eight Products Exceed $1 Billion in Net Sales, FY2008
Eli Lilly net sales activity of major products in 2007 compared with 2006
Eli Lilly products launched this decade
Research and Development investment increasing, 2004-2008
Revenue and net profit of Eli Lilly, 2004-2008
Return on Assets and shareholders’ Equity
Development Pipeline of main products of EpiCept
Revenue and net profit of EpiCept, 2004- 2008
Net sales and Profit by segment, 2006-2008
Prescription pharmaceuticals sales of Schering Plough, 2007-2008
Revenue of Schering Plough by region
Net sales and long-lived assets of Forest, 2006-2008
Net sales by therapeutic class of Forest
Pipeline snapshot of Forest
Strategically focused of Forest
Revenue and net profit of Forest,2004-2008
Financial highlights of Forest,2004-2008
Net sales and long-lived assets of Forest, 2006-2008
Comparison of 5 Year Cumulative Total Return, 2003-2008
Revenue composition of Mylan, 2007-2008
Mylan’s global market leadship, 2008
Significant operational properties of Mylan
Revenue and net profit of Mylan,2004-2008
Comparison of cumulative total returns of Mylan’s Common Stock, the
Standard & Poor’s 500 Composite Index and the Dow Jones U.S. Pharmaceuticals Index, 2003-2008
Sales of Herbalife by Geographic Region, 2007-2008
Sales by product category, 2007-2008
Revenue and net profit of Herbalife, 2004-2008
Comparison of cumulative total returns of Herbalife’s Common Stock,
S&P 500 Composite Index and the Peer Index, 2004-2008
Revenue and net profit of King Pharmaceuticals, 2004-2008
Operating segments of NBTY, 2006-2008
Revenue and net profit of NBTY, 2004-2008
Comparison of 5 year cumulative total return among NBTY, Inc., NYSE
Composite Index and The NYSE Care Index,2003-2008
Perrigo revenue by country and by segment,2008
Manufacturing scale of Perrigo,2008
Sales, volumes and profits of Perrigo by category, 2008
Updated category of Perrigo,2008 
Performance of Generic segment of Perrigo,2008
Performance of API segment of Perrigo, 2008
R&D of Perrigo, 2004-2009
Revenue and net profit of Perrigo, 2004-2008
Perrigo financial performance,2003-2009
Revenue by geography of Life Technologies, 2008
Revenue by end markets of Life Technologies,2008
Basic data of Life Technologies, 2008
Revenue and net profit of Life Technologies,2004-2008
Comparison of 5-year cumulative total return among Life Technologies,
NASDAQ market Index and NASDAQ Pharmaceutical Index,2003-2008
Research and development pipeline of Sepracor,2008
Revenue and net profit of Sepracor,2004-2008
Product portfolio of Endo, 2008
Endo’s net sales by product category, 2006-2008
Revenue and net profit of Endo,2004-2008
Comparison of 5-year cumulative total return among Endo, NASDAQ
market Index and NASDAQ Pharmaceutical Index, 2003-2008
Warner Chilcott’s revenues by product classes, 2006-2008
Revenue and net profit of Warner, 2005-2008
Revenue and net profit of Par,2004-2008
Product portfolio of Valeant
Revenue breakout of Valeant,2008
Valeant revenue by product, 2007-2008
Valeant revenue of branded product, 2006-2008
Revenue and net profit of Valeant,2004-2008
Domestic net sales of Chattem, 2007-2008
Geographical segment information of Chattem, 2006-2008
Revenue and net profit of Chattem, 2004-2008
Prestige net revenue by segments, 2008
Revenue and net profit of Prestige, 2004-2008
Revenue and net profit of Medicines, 2004-2008
Products introduced by Techne, FY1989-2008
Results of Operations of Techne,2006-2008
Revenue and net profit of Techne, 2004-2008
Cambrex Gross sales by product groups, 2006-2008
Cambrex Gross sales by district, 2006-2008
Revenue and net profit of Cambrex, 2004-2008
Product mix of Allion, 2008
Allion Revenue of Specialty HIVand Specialty Infusion business,2008
Allion Operating results of Specialty HIV segment,2007-2008
Revenue and net profit of Allion, 2004-2008
Net product revenues of Salix by product,2005-2007
Salix primary product candidates currently under development
Strategy of Salix
Revenue and net profit of Salix,2004-2008
Comparison of 5-year cumulative total return among SLXP, NASDAQ
composite Index and NASDAQ biotechnology Index, 2003-2008
The mix of U.S.-based sales and ex-U.S. based Manufacturing and Sales of PDL, 2006-2008
Revenue and net profit of PDL, 2004-2008
Comparison of 5-year cumulative total return among PDL, NASDAQ
biotechnology Index and NASDAQ composite Index, 2003-2008
Revenues of Albany Molecular by segment, 2006-2008
Revenue and net profit of Albany Molecular,2004-2008
Comparison of 5-year cumulative total return among Albany Molecular,
NASDAQ Index and NASDAQ Pharmaceuticals Index, 2003-2008
ENZON Product portfolio + PIPELIN E
ENZON segment profitability,2006-2008
ENZON sales performance by product,2006-2008
Revenue and net profit of Enzon,2004-2008
AmerisourceBergen revenue,FY2008
Pharmaceutical distribution revenue of AmerisourceBergen,2005-2008
Acquisition Strategy of AmerisourceBergen
Revenue and net profit of AmerisourceBergen,2004-2008
FY 2008 Results of AmerisourceBergen
Targets of AmerisourceBergen for fiscal year 2009
Long Term Financial Goals of AmerisourceBergen

China Vitamin Industry Report,2014-2017

China is the world's largest production base of vitamins, with vitamin C and vitamin E as its most important products, wherein vitamin C and related products account for more than 60% of its total out...

China Chemical Pharmaceutical Industry Report, 2013-2016

Chemical pharmaceutical consists mainly of chemical drug preparation and active pharmaceutical ingredient (API), and the gross margin of chemical drug preparation industry is generally higher than tha...

China Pharmaceutical Distribution Industry Report, 2013

Thanks to the continuous advancement in new medical reform, China’s pharmaceutical distribution industry has maintained a fairly rapid growth in recent years, with the sales value showed a CAGR of rou...

China Pharmaceutical Glass Packaging Industry Report, 2013-2016

Influenced by the substitution of plastic, aluminum foil and other new packaging materials as well as the declining packaging material purchase prices incurred by the medical reform, China pharmaceuti...

China Chinese Patent Medicine Industry Report, 2013-2016

Chinese patent medicine refers to the certain dosage forms of medicine, under the guidance of TCM (traditional Chinese medicine) theory, made from traditional Chinese medicinal materials in accordance...

Global and China Monoclonal Antibody Industry Report, 2013-2017

Currently, monoclonal antibody agents have been successfully used in the treatment of tumors, cancers and other serious diseases as a heavyweight in the biopharmaceutical industry. In 2009-2012, the m...

Global and China Insulin Industry Report, 2013-2017

As the third largest human health disease following neoplastic disease, cardiovascular and cerebrovascular diseases, the number of diabetic patients has continued growing from 246 million in 2007 to 3...

China Large Volume Parenteral (LVP) Industry Report, 2013-2015

Under the context of China's medical reform and sustainable development of the pharmaceutical market, the output and demand of Large Volume Parenteral (LVP) which is one of the top five Chinese prepar...

China Independent Clinical Laboratory Industry Report,2013-2015

Restricted by the health care system and the medical inspection level (Chinese firms mainly lag behind foreign counterparts in molecular diagnostics and other special tests), Chinese independent clini...

China Vitamin Industry Report, 2012-2015

As a great power of vitamin production and export, China has long been known as the world’s vitamin production base. In recent years, its vitamin exports on external demand accounted for about 80% of ...

China Pharmaceutical Equipment Industry Report, 2012-2015

Driven by the new GMP certification as well as the brisk downstream demand, China pharmaceutical equipment industry has seen steady progress in sales volume and technological content of products over ...

China Genetic Engineering Drug Industry Report, 2011-2012

China gets a late start in developing genetic engineering drug industry, but has achieved leapfrog advance. At present, China has at least one hundred enterprises involved in genetic engineering drugs...

China Animal Vaccine Industry Report, 2011-2012

Along with the frequent outbreaks of animal epidemics, the government’s increasing investment in epidemic prevention and the implementation of compulsory immunization system, Chinese animal vaccine ma...

China Human Vaccine Industry Report, 2011-2012

After decades of development, China has become one of the major producer and consumers of human vaccine around the world. In 2011, human vaccine manufacturers numbered 38 in China and the lot release ...

China Chemical Pharmaceutical Industry Report, 2011

In Jan.-Aug., 2011, the gross industrial output value of Chinese chemical pharmaceutical industry surged by 24.54% YoY to RMB460.531 billion, up 2.67 percentage points over the same period of last yea...

China Pharmaceutical Equipment Industry Report, 2011-2012

In recent years, Chinese pharmaceutical equipment industry has witnessed significant growth in both product quality and technological content, as well as steady rise of sales volume. According to Chin...

China Animal Vaccine Industry Report, 2010-2011

China animal vaccine industry has been fast-growing. The market maintained an average annual growth rate up to 13.6% in 2006-2010, and reached around RMB 7.5 billion in 2010, up 21.0% YoY. With the in...

China Human Vaccine Industry Report, 2010-2011

With the improvement of economy and people’s disease prevention awareness, China’s human vaccine market has expanded in recent years, growing at a CAGR of 24.0% in 2007-2010. In particular, the market...

2005-2014 All Rights Reserved 京ICP备05069564号-1 京公网安备1101054484号